Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) EBIT (2019 - 2025)

Historic EBIT for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to -$44.9 million.

  • Allogene Therapeutics' EBIT rose 3744.11% to -$44.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$227.4 million, marking a year-over-year increase of 2364.43%. This contributed to the annual value of -$273.2 million for FY2024, which is 1664.08% up from last year.
  • Per Allogene Therapeutics' latest filing, its EBIT stood at -$44.9 million for Q3 2025, which was up 3744.11% from -$56.8 million recorded in Q2 2025.
  • Allogene Therapeutics' 5-year EBIT high stood at $1.7 million for Q4 2021, and its period low was -$99.1 million during Q1 2023.
  • Moreover, its 5-year median value for EBIT was -$71.4 million (2024), whereas its average is -$67.6 million.
  • Per our database at Business Quant, Allogene Therapeutics' EBIT skyrocketed by 10246.1% in 2021 and then plummeted by 574704.16% in 2022.
  • Quarter analysis of 5 years shows Allogene Therapeutics' EBIT stood at $1.7 million in 2021, then plummeted by 5747.04% to -$96.4 million in 2022, then increased by 11.71% to -$85.1 million in 2023, then rose by 28.93% to -$60.5 million in 2024, then grew by 25.77% to -$44.9 million in 2025.
  • Its last three reported values are -$44.9 million in Q3 2025, -$56.8 million for Q2 2025, and -$65.2 million during Q1 2025.